Literature DB >> 16642920

Prostaglandin E1 attenuates impairment of cellular immunity after cardiopulmonary bypass.

Tetsuro Sano1, Munetaka Masuda, Shigeki Morita, Hisataka Yasui.   

Abstract

OBJECTIVE: It is well documented that cardiopulmonary bypass (CPB) severely impairs cellular immunity. The objective of this study was to investigate the effect of prostaglandin E1 (PGE1) on cellular immunity after CPB.
METHODS: Patients who underwent elective cardiac surgery were randomly divided into the PGE1 group (n=12) and the control group (n=12). In the PGE1 group, PGE1 was administered at 20 ng/kg/min from just after the induction of anesthesia to the end of surgery. Peripheral blood mononuclear cells (PBMCs) were taken before anesthesia and on postoperative days 1, 3 and 7 (POD 1, POD 3 and POD 7). Proliferation responses of T cells to phytohemagglutinin (PHA) and pure protein derivative (PPD) antigen were measured as indicators of cellular immunity.
RESULTS: PGE1 significantly attenuated the impairment of both PHA and PPD response after cardiac surgery on POD 1 (PHA response, 30 +/- 21% vs. 53 +/- 32%, control vs. PGE, p=0.048; PPD response, 18 +/- 21% vs. 39 +/- 27%, control vs. PGE, p=0.046). The reduced glutathione content of PBMCs in the control group was significantly decreased on POD 1.
CONCLUSION: PGE1 attenuated the impairment of cellular immunity after cardiac surgery with CPB by reducing oxidative stress on PBMCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16642920     DOI: 10.1007/BF02662469

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  14 in total

1.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

Authors:  J Schmielau; O J Finn
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

2.  Cell-mediated immunity is depressed following cardiopulmonary bypass.

Authors:  J A Roth; S H Golub; R A Cukingnan; J Brazier; D L Morton
Journal:  Ann Thorac Surg       Date:  1981-04       Impact factor: 4.330

3.  Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery.

Authors:  T Kawamura; N Nara; M Kadosaki; K Inada; S Endo
Journal:  Crit Care Med       Date:  2000-07       Impact factor: 7.598

4.  Cytotoxic enzyme release and oxygen centered radical formation in human neutrophils are selectively inhibited by E-type prostaglandins but not by PGI2.

Authors:  G Hecker; P Ney; K Schrör
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

5.  Prostaglandin E1 attenuates cytotoxic mechanisms of primed neutrophils.

Authors:  D Y Tamura; E E Moore; D A Partrick; J L Johnson; P J Offner; C C Silliman
Journal:  Shock       Date:  1998-03       Impact factor: 3.454

6.  Preoperative administration of steroids: influence on adhesion molecules and cytokines after cardiopulmonary bypass.

Authors:  U P Schurr; G Zünd; S P Hoerstrup; J Grünenfelder; F E Maly; P R Vogt; M I Turina
Journal:  Ann Thorac Surg       Date:  2001-10       Impact factor: 4.330

7.  Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1.

Authors:  S A Kozek-Langenecker; O Wanzel; R Berger; S C Kettner; F Coraim
Journal:  Anesth Analg       Date:  1998-11       Impact factor: 5.108

8.  Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass.

Authors:  J Katoh; K Tsuchiya; H Osawa; W Sato; G Matsumura; Y Iida; S Suzuki; S Hosaka; S Yoshii; Y Tada
Journal:  J Thorac Cardiovasc Surg       Date:  1998-08       Impact factor: 5.209

9.  Differential regulation of interleukin-6, macrophage inflammatory protein-1, and JE/MCP-1 cytokine expression in macrophage cell lines.

Authors:  C A Martin; M E Dorf
Journal:  Cell Immunol       Date:  1991-06       Impact factor: 4.868

10.  Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation.

Authors:  A Markewitz; E Faist; S Lang; S Endres; D Fuchs; B Reichart
Journal:  J Thorac Cardiovasc Surg       Date:  1993-01       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.